Arctoris was featured in Forbes as part of a wider exploration of how robotics and artificial intelligence are converging to transform drug discovery. The article set the scene for a rapidly growing industry, with robotics in pharma expected to grow from a $2.05 billion sector in 2019 to $4.87 billion by 2023, driven by the urgent need to address the notoriously slow speed, high cost and high failure rates that have long defined the drug development process.
The feature examined how AI and robotic labs work in tandem: AI identifies patterns and possibilities from vast datasets, designing and optimising new molecules at a speed and precision beyond human capability, while robotic labs generate the high-quality, reproducible data that makes those AI systems more accurate and powerful.
Arctoris co-founder and CEO, Tom Fleming, was quoted directly in the piece, noting that historically collected data has been uncertain in terms of value and reliability, and that there are now new and better ways of producing it. This speaks directly to the foundation of what the Ulysses® platform was built to solve: generating precise, reproducible, AI-ready datasets at a scale and consistency that conventional approaches simply cannot match.
The article positioned robotic labs as the final piece of the puzzle in a fully tech-enabled drug discovery process and Arctoris as one of the pioneering companies leading that charge.